News & Press

Patient Perspective: Katie Doble’s Journey with TIL Therapy

March 31, 2022

Guest blog post by Katie Doble, ocular melanoma (OM) survivor, MRF Courage Award recipient and OM advocate: TIL therapy has given my family and me next-level hope. At 31 years old, I received my first cancer diagnosis—primary uveal melanoma, meaning it …

Recent FDA Approvals for the Melanoma Community

March 23, 2022

The Melanoma Research Foundation (MRF) is pleased to share recent significant achievements for the melanoma community. In March 2022, the U.S. Food and Drug Administration (FDA) granted Iovance Biotherapeutics, Inc. an Investigational New Drug Applicat …

FDA Grants Investigational New Drug Application for TIL Therapy

March 18, 2022

On March 15, the U.S. Food and Drug Administration (FDA) granted Iovance Biotherapeutics, Inc. an Investigational New Drug Application (IND) for IOV-4001, its first genetically modified tumor-infiltrating lymphocytes (TIL) therapy to treat unresectable …

MRF Joins 100 Advocacy Organizations in Support of Cancer Moonshot

March 4, 2022

On February 25, 2022, the American Cancer Society Cancer Action Network (ACS-CAN) and the National Comprehensive Cancer Network (NCCN) sent a joint letter to the Majority and Minority Leaders of both Houses of Congress, indicating strong support for th …

Rare Disease Day in the MRF Community

February 25, 2022

As the MRF observes Rare Disease Day on February 28, 2022, we celebrate the courageous and inspiring members of our community who are living with a rare melanoma subtype. Monique (Acral Lentiginous Melanoma): “It is important for me to be an advocate a …